http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-056025-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12 |
| filingDate | 2006-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0df3291781de963fd115dd3c31add267 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6aa4c89df244527f387d994e61e0c1d1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64f3f47b88748990180df97c3b3347d4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92039ad73f42620f61cd11d2d78e73e9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a26dfd7db892501ee2696a00bbf03fd7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79f07066e323bb8910da388a4df6f797 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_791a45a4d9552723b24d9d827f0a0179 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08875fa89cac664543f103097de3ac27 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_717f5c7128d44b0e9fca22547f480b71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17dadcddf576f4bc77ffdacfb318b1e3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e4929ab6755f732293d20cf9b7ac9e66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_79bf515cbb8a8ba554cc4f8dbe077469 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fc8aaed0fdeb5e32f0317857fbead3c2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2310333a8479c5c687160e281fcd1da5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae81f62e44d1f9196efcc94bf0e0f89f |
| publicationDate | 2007-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-056025-A1 |
| titleOfInvention | IMIDAZOL COMPOUNDS REPLACED AS KSP INHIBITORS |
| abstract | Pharmaceutical compositions containing them and therapeutic uses as anticancer agents. Claim 1: A compound characterized in that it responds to formula (1) wherein: R1 is selected from the group consisting of aminoacyl, acylamino, carboxyl, carboxylester, alkyl, and substituted alkyl, with the proviso that substituted alkyl is not substituted with aryl or substituted aryl; R2 is selected from the group consisting of H, alkyl, and aryl; R3 and R4 are independently selected from the group consisting of H, hydroxy, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, and substituted heterocyclic, with the proviso that only 1 of R3 or R4 is hydroxy; or R3 and R4 together with the N atom to which they are attached bind to form a substituted heterocyclic or heterocyclic; R5 is selected from the group consisting of H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl and substituted heteroaryl; or R1 and R5, together with the C and N atoms attached thereto respectively are joined to form a substituted heterocyclic or heterocyclic group; or when R1 and R5, together with the C and N atoms attached thereto respectively, do not form a heterocyclic group, then R4 and R5, together with the atoms attached thereto, form a substituted heterocyclic or heterocyclic group; R8 is selected from the group consisting of L-A1, wherein L is selected from the group consisting of -S (O) q- where q is one or two, and C1-5 alkylene optionally substituted with hydroxy, halo, or acylamino; and A1 is selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, and substituted cycloalkyl; and one of any of R6 or R7 is selected from the group consisting of cycloalkyl, heterocyclic, aryl and heteroaryl, all of which may be optionally substituted with - (R9) m where R9 has the values defined and m is an integer between 1 and 4, and the other of R6 or R7 is selected from the group consisting of H, halo, and alkyl; R9 is selected from the group consisting of cyano, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, -CF3, alkoxy, substituted alkoxy, halo, and hydroxy; and when m is an integer between 2 and 4, then each R9 can be the same or different; or its salts, esters or prodrugs acceptable for pharmaceutical use. |
| priorityDate | 2005-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.